Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY^® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company’s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY^® System, pending marketing clearance by the U.S. Food and Drug Administration (FDA).

Read more at globenewswire.com